Michael Jefford - Concepedia

Author

Michael Jefford

Also Known As

Jefford, M, Jefford, Michael, Linda Jacobs, M Jefford, M. JEFFORD, M. Jefford, Mahesh Iddawela, Michael JEFFORD, Michael Jefford, Moira O’Connor

379

Publications

10.1K

Citations

H-Index

130

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne The University of Sydney Cancer Council Victoria UNSW Sydney

About

Michael Jefford is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and family medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	51	2.4K
2	Health Sciences	5	5	149
3	Education	3	3	150
4	Arts	2	2	130
5	Language Studies	1	1	104

Michael Jefford

125

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets Thomas Luft, Michael Jefford, Petra Luetjens, Blood	2002	354
Management of Cancer and Health After the Clinic Visit: A Call to Action for Self-Management in Cancer Care Doris Howell, Deborah K. Mayer, Richard Fielding, JNCI Journal of the National Cancer Institute Family MedicineSelf-managementCancer ManagementSelf-care InterventionCancer Education	2020	213
Survivorship issues following treatment completion—results from focus groups with Australian cancer survivors and health professionals Michael Jefford, Emily Karahalios, Annabel Pollard, Journal of Cancer Survivorship NursingFamily MedicineFocus GroupsPatient SupportMedicine	2008	149
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial Martin R. Stockler, Rachel O’Connell, Anna K. Nowak, The Lancet Oncology Advanced CancerPlacebo-controlled Double-blindOncologyPsychiatryMood Symptom	2007	149
Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial Lillian L. Siu, Jeremy Shapiro, Derek J. Jonker, Journal of Clinical Oncology	2013	125
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Mark Shackleton, Ian D. Davis, Wendie Hopkins, PubMed ImmunologyImmunoeditingAdjuvant Flt3 LigandImmunotherapeuticsCd4 T Cell Responses	2004	123
The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up Carl Michael Baravelli, Meinir Krishnasamy, Carmel Pezaro, Journal of Cancer Survivorship NursingFamily MedicineBowel Cancer SurvivorsSurvivorship Care PlansEnd-of-life Care	2009	119
IL-1β Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation Thomas Luft, Michael Jefford, Petra Luetjens, The Journal of Immunology	2002	117
Development and Pilot Testing of a Nurse-Led Posttreatment Support Package for Bowel Cancer Survivors Michael Jefford, Kerryann Lotfi‐Jam, Carl Michael Baravelli, Cancer Nursing	2011	114
Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and <i>KRAS</i>-Specific Results of the NCIC CTG and AGITG CO.17 Trial Heather‐Jane Au, Christos S. Karapetis, Chris J. O’Callaghan, Journal of Clinical Oncology	2009	113

Page 1